Aripiprazole
Is It Right for You?
A complete guide to Aripiprazole — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Aripiprazole?
Aripiprazole is an atypical (second-generation) antipsychotic medication used in the treatment of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder. Unlike first-generation antipsychotics — which act as dopamine receptor antagonists — aripiprazole functions as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors. This unique pharmacological profile is described as dopamine system stabilisation, modulating dopaminergic activity up or down depending on the prevailing synaptic environment.
Aripiprazole is available in several formulations: oral tablets (2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg), oral solution (1 mg/mL), orodispersible tablets, and long-acting injectable preparations (Abilify Maintena and Aristada) for patients where adherence to daily oral therapy is a concern.
Compared to many other atypical antipsychotics, aripiprazole has a more favourable metabolic side-effect profile, with lower propensity for weight gain, dyslipidaemia, and glucose dysregulation — though these risks are not eliminated.
Aripiprazole is a prescription-only medication in the UK. Initiation and dose titration should be supervised by a clinician with appropriate experience in psychiatric disorders.
What Conditions Is Aripiprazole Used For?
Aripiprazole is prescribed for a variety of common bacterial infections across multiple body systems:
treatment of positive symptoms (hallucinations, delusions, disorganised thinking) and negative symptoms; licensed for adults and adolescents aged 15 and over
treatment and prevention of manic episodes; licensed as monotherapy and as adjunct to mood stabilisers
adjunctive treatment in adults with inadequate response to antidepressant monotherapy
licensed in adolescents aged 13–17 years in some jurisdictions; use guided by specialist recommendation
used off-label and in some licensed indications for tic suppression
Aripiprazole is an effective tool in managing psychotic and mood symptoms but does not alter the underlying neurobiological basis of schizophrenia or bipolar disorder. Long-term treatment and comprehensive psychiatric care — including psychosocial support, psychotherapy, and structured community follow-up — remain essential components of management.
How Does Aripiprazole Work?
Aripiprazole's mechanism of action differs fundamentally from both first-generation and most other second-generation antipsychotics, through its role as a partial dopamine D2/D3 agonist:
Dopamine partial agonism — in hyperdopaminergic states (associated with positive psychotic symptoms), aripiprazole competes with endogenous dopamine at D2 receptors, producing a net reduction in dopaminergic transmission. In hypodopaminergic states (associated with negative symptoms and depression), its partial agonist activity provides a degree of dopaminergic stimulation. This bidirectional modulation underpins its broader clinical utility.
Serotonin 5-HT1A partial agonism — contributes to anxiolytic and antidepressant-like effects, and may reduce extrapyramidal side effects by modulating dopaminergic tone in nigrostriatal pathways.
Serotonin 5-HT2A antagonism — similar to other atypical antipsychotics, this activity contributes to antipsychotic efficacy and further reduces the propensity for extrapyramidal symptoms relative to first-generation agents.
This profile translates clinically to effective antipsychotic and mood-stabilising activity with a lower risk of hyperprolactinaemia, metabolic syndrome, sedation, and movement disorders than many comparators — though individual responses vary considerably.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Take aripiprazole at the same time each day. Its long half-life of approximately 75 hours (and 94 hours for its active metabolite dehydro-aripiprazole) allows once-daily dosing and provides a substantial buffer against missed doses.
Can be taken with or without food. Food does not significantly affect absorption.
Titrate slowly when initiating. Starting at a low dose (e.g., 2 mg in MDD augmentation; 10–15 mg in schizophrenia) and increasing gradually minimises the risk of akathisia and activating side effects.
Do not stop aripiprazole abruptly without discussing with your clinician. Although aripiprazole does not carry the same physical withdrawal risk as some other psychotropics, abrupt discontinuation can precipitate relapse of the underlying condition.
Long-acting injectable formulations (Abilify Maintena) are administered monthly and are appropriate for patients where daily oral adherence is a challenge. Initiation requires oral aripiprazole overlap for the first two weeks.
Side Effects of Aripiprazole
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Akathisia (inner restlessness, compulsion to move) — among the most common and clinically significant; may be mistaken for worsening anxiety
- Insomnia or sleep disturbance
- Nausea, particularly at initiation
- Headache
- Anxiety or agitation
- Somnolence (less common than with many other antipsychotics)
- Weight gain — lower incidence than with olanzapine or quetiapine, but still possible
- Tremor or other mild extrapyramidal symptoms
- Neuroleptic malignant syndrome (NMS) — rare but potentially fatal; hyperthermia, muscular rigidity, autonomic instability, altered consciousness; discontinue immediately and seek emergency care
- Tardive dyskinesia — involuntary repetitive movements (oro-facial, limb); risk with long-term antipsychotic use; may be irreversible
- Severe akathisia — can increase suicidal ideation if unrecognised and untreated
- Impulse control disorders — pathological gambling, hypersexuality, binge eating, and compulsive spending have been reported; caution patients and carers at initiation
- Orthostatic hypotension — dizziness on standing; falls risk particularly in elderly patients
- Seizures — rare; use with caution in patients with a history of epilepsy
- Suicidal ideation — antidepressants and antipsychotics carry a class-level warning regarding increased suicidal thoughts, particularly in patients under 25 at initiation; monitor closely
Aripiprazole's partial dopamine agonist activity can in some patients produce dopaminergic stimulation in reward pathways, leading to newly emerging or worsening impulse control disorders. Patients and carers should be explicitly counselled about this risk at initiation. If new compulsive behaviours develop, the dose should be reviewed and reduction or discontinuation considered.
Drug Interactions
Always disclose all prescription drugs, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting Aripiprazole'.
These agents significantly increase aripiprazole metabolism, reducing plasma levels by up to 70%. The aripiprazole dose should be doubled when co-prescribed; reduce back to the standard dose upon discontinuation of the inducer.
These agents reduce aripiprazole clearance, increasing plasma concentrations and risk of side effects. The aripiprazole dose should be halved when co-prescribed with strong inhibitors of either pathway.
Additive CNS depression; enhanced sedation and respiratory depression risk. Use with caution; counsel patients about alcohol.
Aripiprazole's alpha-1 adrenergic blocking activity can enhance the hypotensive effects of antihypertensive agents; monitor blood pressure.
Concurrent use with other antipsychotics risks pharmacodynamic interaction; use only under specialist guidance. Dopamine agonists (e.g., for Parkinson's disease) may have their effect antagonised by aripiprazole.
No clinically significant interaction with aripiprazole absorption.
Important Warnings
Antipsychotics, including aripiprazole, are associated with an increased risk of mortality in elderly patients with dementia-related psychosis. Aripiprazole is not licensed for this indication. Use in this population should be exceptional, carefully documented, and subject to regular review.
Aripiprazole, like other psychotropic agents, carries a warning for increased suicidal ideation in children, adolescents, and young adults (under 25) at initiation or dose change. Patients and carers should be advised to monitor for worsening mood, agitation, or suicidal thoughts and to seek urgent review if these emerge.
Akathisia — a feeling of inner restlessness and inability to remain still — is a common and distressing side effect that may be misidentified as worsening anxiety or psychomotor agitation. Clinicians and patients should be alert to this. Dose reduction is usually the first management step; propranolol may be used in persistent cases.
Although aripiprazole has a more favourable metabolic profile than some antipsychotics, baseline and periodic monitoring of weight, fasting glucose, and lipid profile is recommended for all patients on long-term antipsychotic therapy.
Safety data in pregnancy are limited. Antipsychotics should be used during pregnancy only when the clinical benefit clearly outweighs the risk. Neonates exposed to antipsychotics in the third trimester may show extrapyramidal symptoms or withdrawal effects following delivery. Women of childbearing potential should discuss contraceptive planning with their clinician.
No dose adjustment is required in hepatic or renal impairment. Aripiprazole is extensively hepatically metabolised but its clinical pharmacokinetics are not significantly altered in mild-to-moderate impairment. Limited data exist for severe impairment; use with caution.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Aripiprazole FAQs
The onset of antipsychotic effect is gradual. Some improvement in agitation or sleep disturbance may be noticed within the first one to two weeks, but meaningful reduction in psychotic symptoms typically requires four to six weeks of consistent use at therapeutic doses.
Aripiprazole is associated with less weight gain than olanzapine, quetiapine, or clozapine. However, weight gain can still occur, particularly at higher doses or in younger patients. Monitoring weight regularly and maintaining a healthy lifestyle is recommended.
Akathisia is a feeling of inner restlessness, an urge to keep moving, and an inability to sit still. It is one of the more common side effects of aripiprazole and can be distressing. If you experience this, contact your clinician — dose reduction or switching formulation is usually effective.
Alcohol is a CNS depressant and may enhance sedation and dizziness when combined with aripiprazole. Patients are advised to avoid or minimise alcohol during treatment.
You should not stop aripiprazole without discussing it with your clinician first. Feeling well is often a sign that the medication is working. Stopping abruptly can lead to relapse of schizophrenia or bipolar disorder. Any decision to discontinue should involve a planned, gradual taper under clinical supervision.
Yes — impulse control disorders including pathological gambling, hypersexuality, and compulsive eating or spending have been reported with aripiprazole. If you notice any new or worsening impulsive behaviours, contact your clinician promptly.